Scholarlink

Introduction <p>This study investigated early anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated with 8&#xa0;mg aflibercept compared to patients treated with the standard dose of 2&#xa0;mg aflibercept using spectral domain optical coherence tomography (SD-OCT), microperimetry, and macular pigment optical density (MPOD) after loading phase administration.</p> Methods <p>This prospective, observational study included 30 eyes of 30 patients (mean age 70 ± 5&#xa0;years; 15 male, 15 female) recruited between January and June 2025 at the Eye Clinic of the University of Naples “Federico II”. Patients were assigned to one of two age- and gender-matched groups receiving intravitreal injections of aflibercept at the dose of 2&#xa0;mg (group&#xa0;A) or 8&#xa0;mg (group&#xa0;B). All patients underwent complete ophthalmological examination, SD-OCT, OCT angiography, microperimetry, fixation stability, and measurement of MPOD at baseline, month&#xa0;2, and month&#xa0;4.</p> Results <p>Group&#xa0;B showed an improvement in all parameters, compared to group&#xa0;A, in particular: a greater reduction in central macular thickness (CMT) (<i>p</i> = 0.008), an improvement in best-corrected visual acuity (BCVA) (<i>p</i> = 0.012), increased retinal sensitivity (<i>p</i> = 0.015), increased MPOD (<i>p</i> = 0.027), and reduced bivariate contour ellipse area (BCEA) (<i>p</i> = 0.039). Group&#xa0;B showed a faster drying rate during the first 2&#xa0;months (70 vs. 40&#xa0;μm/month) and overall at month&#xa0;4.</p> Conclusions <p>Intravitreal injections of aflibercept 8&#xa0;mg resulted in significant short-term anatomical and functional improvement compared to standard dose and thus appear to be an effective option to achieve faster results in nAMD. MPOD can be considered as a potential new biomarker of macular health to study retinal functional response.</p> Trial Registration <p>The research protocol was registered on ClinicalTrials.gov (NCT07074054).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aflibercept 8 mg in Neovascular AMD—A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Michele Rinaldi,
  • Gilda Cennamo,
  • Marina Concilio,
  • Gaetano Corvino,
  • Alessia Riccardo,
  • Raffaele Nubi,
  • Ciro Costagliola

摘要

Introduction

This study investigated early anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated with 8 mg aflibercept compared to patients treated with the standard dose of 2 mg aflibercept using spectral domain optical coherence tomography (SD-OCT), microperimetry, and macular pigment optical density (MPOD) after loading phase administration.

Methods

This prospective, observational study included 30 eyes of 30 patients (mean age 70 ± 5 years; 15 male, 15 female) recruited between January and June 2025 at the Eye Clinic of the University of Naples “Federico II”. Patients were assigned to one of two age- and gender-matched groups receiving intravitreal injections of aflibercept at the dose of 2 mg (group A) or 8 mg (group B). All patients underwent complete ophthalmological examination, SD-OCT, OCT angiography, microperimetry, fixation stability, and measurement of MPOD at baseline, month 2, and month 4.

Results

Group B showed an improvement in all parameters, compared to group A, in particular: a greater reduction in central macular thickness (CMT) (p = 0.008), an improvement in best-corrected visual acuity (BCVA) (p = 0.012), increased retinal sensitivity (p = 0.015), increased MPOD (p = 0.027), and reduced bivariate contour ellipse area (BCEA) (p = 0.039). Group B showed a faster drying rate during the first 2 months (70 vs. 40 μm/month) and overall at month 4.

Conclusions

Intravitreal injections of aflibercept 8 mg resulted in significant short-term anatomical and functional improvement compared to standard dose and thus appear to be an effective option to achieve faster results in nAMD. MPOD can be considered as a potential new biomarker of macular health to study retinal functional response.

Trial Registration

The research protocol was registered on ClinicalTrials.gov (NCT07074054).